| 货号 | HB651056 |
|---|---|
| 品牌 | abinScience |
| 种属反应性 | Human |
| 应用 | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
| 宿主 | Human |
| 同种型 | IgG1-kappa |
| 表达系统 | Mammalian Cells |
| 克隆类型 | Monoclonal |
| 靶标 | CD152, Cytotoxic T-lymphocyte protein 4, CTLA-4, CTLA4, Cytotoxic T-lymphocyte-associated antigen 4 |
| 内毒素水平 | Please contact the lab for this information. |
| 纯度 | >95% purity as determined by SDS-PAGE. |
| 纯化方式 | Protein A/G purified from cell culture supernatant. |
| Accession号 | P16410 |
| 状态 | Liquid |
| 保存溶液 | 0.01M PBS, pH 7.4. |
| 稳定性和存储 | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
| 别名 | BCD-145, 2168561-20-2 |
| 背景 | HY-P990945 is an CTLA4-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001). • The blockade of immune checkpoints in cancer immunotherapy., PMID:22437870 • CTLA-4: a moving target in immunotherapy., PMID:29118008 • CTLA-4: From mechanism to autoimmune therapy., PMID:32007707 • Immune Checkpoint Blockade in Cancer Therapy., PMID:25605845 • Immune-related adverse events with immune checkpoint blockade: a comprehensive review., PMID:26765102 • Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy., PMID:27079802 • CD28 Costimulation: From Mechanism to Therapy., PMID:27192564 • Association Between., PMID:35271496 • Immune checkpoint inhibitors., PMID:30760493 • Targeting cytotoxic lymphocyte antigen 4 (CTLA-4) in breast cancer., PMID:38956700 |
| Note | For research use only. Not suitable for clinical or therapeutic use. |
Detects CD152/CTLA4 in indirect ELISAs.
7X24小时产品咨询热线：027--87433958(9:00-18:00)，或扫描下方产品专员二维码或在线留言
武汉东湖新技术开发区神墩四路666号研发楼B区3层东
24小时产品查询
扫一扫关注我们
专属渠道经理
